Navigation Links
NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results

LAWRENCE, Mass., Feb. 28, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the three and twelve months ended December 31, 2012, that includes revenue above the top end of its guidance range.

(Logo: )

Revenue for the full-year 2012 increased 11 percent to $242.1 million, compared with revenue of $217.3 million for the full-year 2011.  Revenue for the fourth quarter of 2012 increased 14 percent to a record $65.0 million compared with revenue of $57.0 million for the fourth quarter of 2011.  The increase in both periods was led by the Company's solid performance in the Home market as a result of growing adoption of more frequent home hemodialysis with the NxStage System One.

Consistent with the Company's guidance, Home delivered 14 percent annual growth, with revenue increasing to $123.6 million for the full-year 2012 compared with revenue of $108.5 million for the full-year 2011.  Home revenue increased to $31.4 million in the fourth quarter of 2012 compared with revenue of $28.2 million in the fourth quarter of 2011, representing an 11 percent increase.  As expected, growth in the Home for the fourth quarter of 2012 was negatively impacted by the timing of capital equipment purchases from international distributors in the quarter.

Critical Care delivered 13 percent annual growth, with revenue increasing to $39.5 million for the full-year 2012 compared with revenue of $35.0 million for the full-year 2011.  Revenue in Critical Care increased to $11.3 million in the fourth quarter of 2012, compared with revenue of $9.8 million in the fourth quarter of 2011, representing a 15 percent increase.

The Company's in-center business, Medisystems, delivered 4 percent annual growth with revenue increasing to $76.9 million for the full-year 2012, compared with revenue of $73.8 million for the full-year 2011.  Fourth quarter 2012 revenue was $21.5 million, compared with $19.0 million in the fourth quarter of 2011. The Company also reported $2.1 million in Other Revenues for the full-year 2012, reflecting the Company's dialyzer manufacturing revenue from Asahi.

NxStage reported a net loss of $15.2 million or $(0.26) per share for the full-year 2012 compared with a net loss of $21.4 million or $(0.39) per share for the full-year 2011.  The Company reported a net loss of $2.4 million or $(0.04) per share for the fourth quarter of 2012 compared with a net loss of $4.6 million or $(0.08) per share for the fourth quarter of 2011.

For the full-year 2012, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses, of $8.0 million, compared with $7.3 million for the full-year 2011.  For the fourth quarter of 2012, Adjusted EBITDA was $2.1 million compared with $2.0 million in the fourth quarter of 2011.  (See the exhibits for a reconciliation of this non-GAAP measure.)

"As evidenced by our 2012 results, our business and market fundamentals remain strong and positive. We believe NxStage is uniquely positioned for growth as it continues to make a difference to people's lives with significant innovations that are advancing the standard of renal care," stated Jeffrey H. Burbank, Founder and Chief Executive Officer. 

In commenting on the Company's recent advancements in its product pipeline, which include CE Mark approval for nocturnal home hemodialysis with the System One, its high flow dialysis capabilities, and its revolutionary single needle technology, Burbank stated, "Taken together with increasing confidence in our ability to drive continued growth with new direct to patient marketing programs, we believe the overall effect of our product execution is that we are better positioned to accelerate adoption of our therapies with much greater potential than in the past.  With the benefit of these programs largely expected in 2014, we expect top line 2013 revenue to remain strong and grow at a rate similar with 2012, followed by accelerated success and over 15% annual revenue growth in 2014 and beyond, excluding any benefit of service revenue from NxStage owned centers of excellence."

Separately, the Company announced plans to transition to a direct sales operation from a distribution relationship in the UK. The Company anticipates that this action will further strengthen its relationships with local customers and position it to more rapidly take advantage of new product approvals. 

This release contains a non-GAAP financial measure; a reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.


For the first quarter of 2013, the Company expects revenue to be in a range of $60.5 and $62.0 million, which includes an expected one-time reduction to revenue of approximately $0.5 - $1.0 million related to its plan to transition to a direct sales operation from a distribution relationship in the UK.  This accounting is expected to result in first quarter 2013 Home revenue being essentially flat with the fourth quarter of 2012. The Company expects a net loss in the range of $4.5 to $5.5 million or $(0.08) to $(0.09) per share.

For the full fiscal year 2013, the Company is forecasting revenue to be between $265 and $270 million, and a net loss in the range of $13 to $17 million or $(0.22) to $(0.28) per share.

Conference Call:NxStage will also host a conference call today, Thursday, February 28, 2013 at 9:00 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at

A replay of the conference call will be available 2 hours after the completion of the call through March 7, 2013.  To access the replay dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 90444810.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Kristen K. Sheppard, Esq.
VP, Investor Relations

Non-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

 NxStage Medical, Inc.Consolidated Statements of Comprehensive Loss(in thousands, except per share data)(unaudited)Three Months Ended
December 31,Twelve Months Ended
December 31,2012201120122011Revenues





217,256Cost of revenues

39,66135,851149,324139,648Gross profit

25,35921,17092,80877,608Operating expenses:Selling and marketing

10,4799,52540,48537,550Research and development


5,0434,61818,88817,916General and administrative

7,0576,45627,53023,206Total operating expenses

27,26924,342104,01493,109Loss from operations

(1,910)(3,172)(11,206)(15,501)Other expense:Interest expense

(91)(1,201)(2,766)(4,714)Other (expense) income, net

(30)54(148)(288)(121)(1,147)(2,914)(5,002)Net loss before income taxes

(2,031)(4,319)(14,120)(20,503)Provision for income taxes

3332451,033899Net loss





(21,402)Net loss per share, basic and diluted





(0.39)Weighted-average shares outstanding, basic and diluted

59,07654,99757,89054,217Other comprehensive loss:Foreign currency gain (loss)





(136)Other (loss) gain

(110)(4)413(17)Comprehensive loss






 NxStage Medical, Inc.Consolidated Balance Sheets(in thousands, except share data)(unaudited)December 31,20122011ASSETSCurrent assets:Cash and cash equivalents



102,909Accounts receivable, net


33,50432,775Prepaid expenses and other current assets

2,5342,777Total current assets

161,467154,269Property and equipment, net

36,32017,599Field equipment, net

10,10112,182Deferred cost of revenues

38,02841,132Intangible assets, net


42,42142,698Other assets

3,7931,213Total assets



291,708LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable



15,634Accrued expenses

20,40015,165Other current liabilities

2,187—Total current liabilities

39,23230,799Deferred revenues

59,26257,014Long-term debt

—43,235Other long-term liabilities

15,8649,474Total liabilities

114,358140,522Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;  no shares issued and outstanding as of December 31, 2012 and 2011

——Common stock: par value $0.001, 100,000,000 shares authorized; 59,850,117 and 56,167,090 shares issued as of December 31, 2012 and 2011, respectively

5956Additional paid-in capital

551,594489,542Accumulated deficit

(344,981)(329,828)Accumulated other comprehensive income (loss)

470(68)Treasury stock, at cost: 541,584 and 480,923 shares as of December 31, 2012 and 2011, respectively

(9,551)(8,516)Total stockholders' equity

197,591151,186Total liabilities and stockholders' equity




 NxStage Medical, Inc.
Cash Flows from Operating Activities
(in thousands)
(unaudited) Twelve Months Ended
December 31,20122011Cash flows from operating activities:Net loss



(21,402)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation and amortization

23,67323,087Stock-based compensation


3,5173,064Changes in operating assets and liabilities:Accounts receivable


(14,545)(16,371)Prepaid expenses and other assets

(1,623)(1,491)Accounts payable

839(1,047)Accrued expenses and other liabilities

5,263(324)Deferred revenues

(3,992)1,648Net cash provided by (used in) operating activities




 NxStage Medical, Inc.Revenues by Segment(in thousands)(unaudited)Three Months Ended
December 31,Twelve Months Ended
December 31,2012201120122011System One segmentHome





108,489Critical Care

11,2839,79239,54034,991Total System One segment

42,70138,005163,129143,480In-Center segment








 NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months Ended
December 31,Twelve Months Ended
December 31,2012201120122011Net loss





(21.4)Less: Depreciation, amortization, interest, and taxes Adjusting items*

(2.1)(0.5)(4.4)(0.3)Adjusted EBITDA





7.3* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses 

SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):